Bicycle Therapeutics (BCYC) Restructuring Costs (2024 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Restructuring Costs came in at $2.0 million in Q2 2026, down 15.21% YoY from $2.3 million in Q2 2025, and down 22.23% on a QoQ basis from $2.5 million in Q1 2026.
Bicycle Therapeutics (BCYC) Restructuring Costs (2024 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 3 years of Restructuring Costs data on file, last reported at $2.0 million in Q2 2026.
- Quarterly Restructuring Costs fell 15.21% year-over-year to $2.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.6 million (down 0.71% YoY) and the FY2025 annual result came in at $9.6 million, up 5.86% from the prior year.
- Restructuring Costs declined to $2.0 million in Q2 2026, from $2.5 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $2.6 million in Q4 2024 to a low of $1.9 million in Q2 2024.
- A 3-year average of $2.3 million and a median of $2.4 million in 2025 frame the typical range for Restructuring Costs.
- Annual changes were most pronounced in 2025 — Restructuring Costs climbed 21.45% — and 2026, when it retreated 15.21%.
- Tracing BCYC's Restructuring Costs over 3 years: stood at $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025, then fell by 23.65% to $2.0 million in 2026.
- The last three Restructuring Costs figures came in at $2.0 million (Q2 2026), $2.5 million (Q1 2026), and $2.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.97 Mn |
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 1.92 Mn |
| Mar 31, 2024 | 2.02 Mn |